Vivek Sharma
Alembic Pharmaceuticals Limited reported a strong performance in its Q1 results for the period ending June 30, 2024, primarily driven by robust sales in the US market. Alembic Pharmaceuticals has a strong presence in the US market, which is a key driver for its growth. In Q1 FY25, the company reported a 6% increase Read more: Alembic Pharmaceuticals Q1 Reports 12% profit rise amid strong US Market sales..
Share Market Closing Bell: On Thursday, August 8, 2024, the Share market closed in the red after the Reserve Bank of India (RBI) decided to keep the repo rate unchanged at 6.5%. The Sensex closed at 582 points down at 78,886.22, Nifty concluded at 180.50 points down at 24,117.00 and Nifty Bank just closed Read more: Share Market Closing Bell: Sensex, Nifty closed in the red after RBI to keep repo rate unchanged..
Suzlon’s stock is experiencing a remarkable surge! The past year’s performance of 292.74% and 32% in the past month shows significant increase as on 8 Aug, 3:30 pm IST, bringing the company back into the spotlight, reminiscent of the excitement surrounding its initial stage. Suzlon’s efforts to restructure its debt have been successful, reducing its financial Read more: Suzlon stock is back, NSE: SUZLON surged 292.74% past year and 32% past month..